China China’s healthcare system, which impacts 1.4 billion people, is facing serious capacity issues at all stages of the value chain. Against this backdrop, the country is looking at making wholesale changes across the system but with a very pragmatic approach that reflects former leader Deng Xiaoping’s famous adage ‘crossing the…

China Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at the top leadership level but throughout the organization. A few country managers share their talent strategies, as well as the…

Pharma Faces 2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From an International Trainee role at BI HQ, he moved into finance, where he stayed for a decade, with stints in…

Puerto Rico A long list of multinational pharma companies count Puerto Rico as one of their top manufacturing bases, including 11 of the top 20 global pharma companies. Puerto Rico also manufactures half of the 2018 world’s top 10 bestselling drugs, underscoring the fact that the island is a pharma production powerhouse.…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies.   Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer…

Opinion Dr Valters Bolevics, CEO of the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) in Latvia, gives an overview of recent market changes affecting the Latvian pharmaceutical market, regulatory upgrades, and growth projections for 2020.   Following a breakthrough year in 2018, 2019 has also seen numerous positive changes for the…

Spain Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences value chain.   With the Iberian nation enjoying an economic rebound, pharmaceutical multinationals are once again seeing Spain as a…

Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…

Puerto Rico Puerto Rico is home to the manufacturing plants for many of the world’s top pharmaceutical and medical device companies, providing a steady stream of treatments to the neighbouring US market and further afield. Here are four facts about Puerto Rican pharma manufacturing that may surprise you.   Fact 1: Puerto…

Opinion Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements – infrastructure, regulations, and the availability of Asia-specific data – to ensure AI can be effectively utilised to improve patient outcomes in the region.   Healthcare, manufacturing,…

Thailand Thailand is known around the world for its lush landscapes, ancient architecture and breathtaking beaches. The nation receives more than 35 million visitors each year. Thailand ranked 4th globally for adventure value and 7th for cultural heritage in US News’ 2017 Best Countries Report, and Bangkok consistently ranks among the…

China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…